Overview: IGVH Mutation Screen TestIntroduction: The IGVH Mutation Screen Test screens for immunoglobulin heavy chain variable region (IGVH) mutations to assess leukemia prognosis, aiding treatment decisions. Following 2023 NCCN guidelines, it uses PCR for high specificity, supporting cancer screening. This test is critical for guiding treatment planning, predicting outcomes, and improving prognosis in molecular pathology for patients with suspected chronic lymphocytic leukemia (CLL).
Other Names: IGVH Mutation Screening Assay, CLL Mutation Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: IGVH mutation screening began in the 1990s with CLL research. PCR-based methods improved in the 2000s, enhancing prognostic accuracy.
Purpose: Screens for IGVH mutations to assess leukemia prognosis, guides treatment, and evaluates patients with suspected CLL.
Test Parameters: 1. IGVH Mutations
Pretest Condition: No fasting required. Collect whole blood, bone marrow, or saliva at any time. Report history of leukemia, lymphadenopathy, or fatigue.
Specimen: 2-5 mL whole blood (EDTA), 2-5 mL bone marrow (EDTA), or 1-2 mL saliva (sterile container). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document leukemia history, lymphadenopathy, fatigue, or prior treatments (e.g., chemotherapy). Include current medications and recent symptoms.
Consent: Written consent required, detailing the tests purpose, prognostic implications, and potential need for leukemia treatment planning.
Procedural Considerations: Uses PCR to screen for IGVH mutations. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for CLL screening.
Factors Affecting Result Accuracy: Improper sample handling, contamination, or low DNA quality can affect results. Recent treatments may influence mutation detection.
Clinical Significance: Mutated IGVH suggests better CLL prognosis, guiding less aggressive treatment. Unmutated IGVH indicates poorer prognosis, requiring confirmatory testing.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation and treatment planning.
Additional Supporting Tests: IGVH hypermutation confirmatory test, flow cytometry, or FISH for CLL to confirm prognosis.
Test Limitations: Screening test; confirmatory testing is needed for definitive prognosis. Other genetic markers may influence outcomes.
References: NCCN CLL Guidelines, 2023; Blood, Hamblin TJ, 2022.
